Abstract
Objective:
Can biochip arrays identify which individuals with metastatic disease will respond to an anti-metastatic agent?
Design and methods:
Cytokine and cell adhesion arrays (Randox Ltd) were measured over 1 month in 9 research participants receiving CTCE-9908 in a Phase I/II study.
Results:
Research participants with stable disease (n=2) had significantly higher soluble VCAM-1 as compared to those that progressed.
Discussion:
VCAM-1 measurement early during CTCE-9908 treatment might be used as a surrogate for response.
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / analysis*
-
Cell Adhesion Molecules / blood
-
Cytokines / blood
-
Demography
-
Drug Screening Assays, Antitumor
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Metastasis / drug therapy*
-
Peptides / therapeutic use*
-
Protein Array Analysis / methods*
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
CTCE-9908
-
Cell Adhesion Molecules
-
Cytokines
-
Peptides